title: Enhanced depth imaging optical coherence tomography of the choroid in Vogt-Koyanagi-Harada disease.
abstract: OBJECTIVE
  Optical coherence tomography (OCT) using enhanced depth imaging (EDI) allows evaluation of choroidal thickness. Our objective was to analyze subfoveal choroidal thickness by EDI-OCT before and after the initiation of high-dose corticosteroid treatment in 8 patients (16 eyes) with new-onset acute Vogt-Koyanagi-Harada (VKH) disease.
  
  
  METHODS
  Retrospective review of clinical records.
  
  
  RESULTS
  The outer border of the choroid was not evident by EDI-OCT in any patients at presentation. Subfoveal choroidal thickness was measurable by 1 week after the initiation of treatment (mean, 578 μm) and decreased thereafter (mean at 1 month, 397 μm; 3 months, 392 μm; 6 months, 384 μm; 12 months, 332 μm). Rebound of choroidal thickening was observed in three patients (five eyes) during corticosteroid tapering in the absence of other evidence of increased inflammation. Peripapillary atrophy was present at 12 months in 6 of 6 eyes that had a choroidal thickness >550 μm at 1 week after initiating treatment, in contrast to none of the 8 eyes with a choroidal thickness ≤550 μm (P = 0.0003).
  
  
  CONCLUSIONS
  Enhanced depth imaging-optical coherence tomography revealed decreasing choroidal thickness with high-dose corticosteroid treatment in our patients. Choroidal thickness as measured by EDI-OCT may serve as a marker for degree of choroidal inflammation in acute VKH disease.
authors.affiliation: Department of Ophthalmology, Kyorin University School of Medicine, Tokyo, Japan.
authors.forename: Makiko
authors.initials: M
authors.lastname: Nakayama
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Keino
authors.forename: Annabelle A
authors.initials: AA
authors.lastname: Okada
authors.forename: Takayo
authors.initials: T
authors.lastname: Watanabe
authors.forename: Wakako
authors.initials: W
authors.lastname: Taki
authors.forename: Makoto
authors.initials: M
authors.lastname: Inoue
authors.forename: Akito
authors.initials: A
authors.lastname: Hirakata
mesh_terms: D000208:Acute Disease; D000284:Administration, Oral; D000328:Adult; D000368:Aged; D002829:Choroid / Q000473:pathology*; D005260:Female; D005451:Fluorescein Angiography; D005938:Glucocorticoids / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage; D008875:Middle Aged; D011239:Prednisolone / Q000627:therapeutic use; D020551:Pulse Therapy, Drug; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D014607:Uveomeningoencephalitic Syndrome / Q000175:diagnosis* / Q000188:drug therapy
chemical_list: D005938:Glucocorticoids; D011239:Prednisolone; D008775:Methylprednisolone